Since the publication of the first X-ray structure of a GPCR (G-protein couple receptor) in 2000, the rate at which subsequent ones have appeared has steadily increased. This has required the development of new methodology to overcome the challenges presented by instability of isolated GPCRs, combined with a systematic optimization of existing approaches for protein expression, purification and crystallization. In addition, quality control measures that are predictive of successful outcomes have been identified. Repeated attempts at solving the structures of GPCRs have highlighted experimental approaches that are most likely to lead to success, and have allowed definition of a first-pass protocol for new receptors.
Introduction
Determining the structures of proteins by X-ray diffraction relies on generating milligram quantities of pure, correctly folded material, which can form well-ordered crystals of sufficient size and stability for data collection. For many years, the lack of suitable protein and crystals represented major barriers for structural studies of integral membrane proteins, including GPCRs (G-protein-coupled receptors), which form the largest class of targets for pharmaceutical intervention. The determination of the structure of rhodopsin in 2000 [1] showed what could be achieved when working with a relatively stable and abundant GPCR, and prompted the development of new approaches to overcome the technical challenges presented by other members of this family. A total of 7 years elapsed before the structure of another was reported [2] , but since then progress has quickened and by mid-2012, structures have been reported for 15 different GPCRs, from the aminergic, purinergic, chemokine, lipid and opioid receptor classes [3] . The availability of these structures, in different conformational states, has greatly increased our understanding of the mechanisms of ligand recognition and receptor activation. In addition, their increasing number is enabling structure-based approaches to become a reality in GPCR drug discovery [3] .
Modification of the expression construct
The lack of stability of native GPCRs when removed from membranes and their conformational flexibility are both impediments to crystallization for structural studies, and all structural efforts since rhodopsin have involved manipulation of the expression construct to address one or both of these issues. One approach has been to introduce mutations to reduce the flexibility of the receptor and increase its stability, Key words: detergent, G-protein-coupled receptor, membrane protein, thermostability. Abbreviations used: DDM, dodecylmaltoside; GFP, green fluorescent protein; GPCR, G-proteincoupled receptor; ICL3, intracellular loop 3; IMAC, immobilized metal-ion-affinity chromatography; LCP, lipidic cubic phase; OTG, octylthioglucoside; PTM, post-translational modification; S1P1, sphingosine-1-phosphate 1; SEC, size exclusion chromatography; FSEC, fluorescence-detection SEC; SPR, surface plasmon resonance; StaR, stabilized receptor; T4L, T4 lysozyme; VD, vapour diffusion. 1 To whom correspondence should be addressed (fiona.marshall@heptares.com).
which is measured via the melting point (the temperature at which unfolding occurs) [4] . The progressive increase in thermostability and the associated increase in yield of receptor as stabilizing mutations are added are shown in Figure 1 . GPCRs that are stabilized to the level seen with bovine rhodopsin are considered stable enough to progress to crystallization, and are referred to as StaRs (stabilized receptors) [5] . Increasing the level of thermostability has been shown to correlate with improved crystallizability and resolution of the final structure [4] . This approach has been used successfully to obtain crystal structures of the β 1 -adrenergic [6] , adenosine A 2A [7, 8] and neurotensin [9] receptors, with each receptor locked into a specific conformational state. Thermostabilizing the A 2A receptor in both agonist and antagonist conformations has enabled structures of a pair of active and inactive states to be compared [8] . Heptares Therapeutics has applied the conformational thermostabilization approach to over 20 different GPCRs across all major target classes including family A, family B and family C receptors.
An alternative strategy is to add a fusion partner to the GPCR to increase crystal contacts and facilitate the ability of the protein to crystallize rapidly while it remains folded [10] . The insertion of T4L (T4 lysozyme) into ICL3 (intracellular loop 3) of a GPCR has been the most widely used approach, resulting in the structures of 11 GPCRs so far [10] . The precise positioning of the fusion protein within the GPCR sequence is critical in minimizing perturbations to the structure while reducing flexibility that might otherwise impede crystallization. Several other fusion protein candidates have now been identified, which can be placed in different positions along the GPCR sequence. Recently, thermostabilized apocytochrome b562RIL was used as an alternative fusion to T4L in ICL3 of the A 2A receptor, resulting in a 1.8 Å (1 Å = 0.1 nm) structure [11] , and has also been placed at the N-terminus of the nociceptin receptor to facilitate structure determination [12] . and represents a bottleneck for structural studies. A variety of expression systems have been tried with bacteria, yeast, insect cells and mammalian cells, all producing proteins of crystallization quality for some receptors. In all cases, it is important to determine the correct folding of the expressed protein, for example by radioligand binding, as in some cases overexpression can lead to misfolding.
Bacterial expression systems are attractive for their ease of use and scalability. Unfortunately, they lack the machinery for most PTMs (post-translational modifications), which may be critical for functional receptor expression. Furthermore, the membranes of bacteria and eukaryotes differ markedly in lipid composition (e.g. cholesterol), which can affect receptor stability [13] . Nonetheless, bacterial systems have been used successfully to overexpress a number of GPCRs, achieving good yields of functional receptor [14] .
Yeast possesses several characteristics beneficial for the large-scale expression of GPCRs. Cultures can be grown quickly, to high densities and at low cost. Yeast can perform the majority of PTMs, although the composition of modifications is often different from that observed in mammalian cells [15] . Several yeast species can produce functional GPCRs, and expression in Pichia pastoris allowed the structure determination of the histamine H 1 receptor [16] .
To date, the insect cell approach has been the gold standard for producing GPCRs for structure determination. Milligram quantities of high-quality protein can be produced [17, 18] , and commercially available systems are efficient and easy to use. Most mammalian PTMs can be performed by insect cells, although the glycosylation pattern can differ and can hinder the expression of mature GPCR protein [19] . Differences in the composition of the membrane can be reduced by the addition of lipid mixtures [20] . Structure determination has been achieved for a growing number of GPCRs expressed in different insect cell types, such as Tni (Trichoplusia ni) and Sf9 (Spodoptera frugiperda 9) [2,6-8,12,21-24].
Expression of GPCRs in native mammalian cells provides the most authentic machinery for production of high-quality protein and has been used to express a wide range of GPCRs [14] . Successful approaches include transient expression, stable cell lines, inducible systems and viral vectors. Optimization of the expression conditions has led to high levels of functional receptor [14, 25] , but factors such as cost and scalability limit the utility of mammalian cells. Nonetheless, considerable success has been obtained with this system, resulting in the determination of the structures of several rhodopsin variants [26, 27] .
Purification
Crystallization of GPCRs requires robust protocols to be developed that allow the purification of homogeneous, monodisperse protein, while maintaining a reasonable yield. The purification of GPCRs is complicated by a number of factors including low abundance, poor stability and structural plasticity leading to multiple conformations. Despite this, several non-rhodopsin GPCR structures have been solved from protein purified using a broadly similar strategy of single or multiple affinity steps.
Extraction of the GPCRs from cell membranes and solubilization for purification requires the use of detergents. The most commonly used detergent is DDM (dodecylmaltoside), which is relatively mild, and enables many receptors to be handled as a single, active monodisperse species, even without thermostabilization. The presence of a ligand is required, however, to provide stability during purification. The low expression of receptors means that the initial step in any purification has to involve an affinity step to enrich the protein sample. The most commonly used affinity tags are the hexa-His [6] and deca-His [7] , which allow purification by IMAC (immobilized metal-ion-affinity chromatography). Nickel [18] and cobalt [28] matrices have been used for the purification of GPCRs, for example the S1P 1 (sphingosine-1-phosphate 1) structure [23] relied on a single TALON ® IMAC purification step. The position of the His-tag (Nor C-terminal) can have a significant effect on the level of protein expression and the efficiency of GPCR binding to the resin. In addition, the tag may have to be removed prior to crystallization [8, 29] . Antibody-based affinity tags have also been applied to the purification of the β 2 -adernergic receptor [30] , opioid receptors [29, 31] and rhodopsin [32] .
Classical methods such as ion exchange (for example, using hydroxyapatite) [33] and SEC (size exclusion chromatography; for example, using Superdex 200) [7] can be used for GPCRs, although the efficiency of protein separation by SEC is often poor in detergents with large micelles. One of the most useful techniques in GPCR purification is ligand-affinity chromatography. Ligand-affinity columns have been used to purify GPCRs from native sources [34] . Resins with covalently bound ligands such as ABT (aminobenztropine) [33] and alprenolol [30] have been used to purify GPCRs for structural studies. The major advantage of ligand-affinity chromatography is that only correctly folded functional receptors will bind to the resin. Although affinity chromatography has a number of benefits, it can suffer from low binding or poor elution; in addition, these matrices often need to be chemically synthesized since they are not commercially available.
Analytical methods
Protein homogeneity is an important consideration for crystallization, and quality control monitoring is required throughout the purification process. PAGE can be used for GPCRs to estimate protein mass and purity (Figure 2A) , and recent advances in sample preparation have made accurate mass determination by MS feasible [35] (Figure 2B ). Accurate mass determination is important for GPCRs, as heterogeneity can arise from sources such as PTMs. For a sample with a unique mass, heterogeneity can still be detected in the association state of the protein. The use of techniques such as SEC provides a good indication of the mono-or poly-disperse nature of purified protein. The use of FSEC (fluorescence-detection SEC), either through the coupling of a fluorescent tag in the form of GFP (green fluorescent protein) [16] or the intrinsic tryptophan fluorescence of the receptor, allows for a very sensitive assay (Figure 3) . GFPbased FSEC also has the advantage that protein straight from cell lysates can be analysed, thus allowing for a much higher throughput screen of conditions.
Owing to the inherent instability of GPCRs when removed from membranes, considerable attention is paid to finding conditions to maximize stability and minimize unfolding. Thermostability can be used to assess whether the solubilizing conditions are optimal. This can be measured with CD, differential scanning calorimetry or by binding fluorescent dyes that can detect protein unfolding by, for example, binding to exposed cysteine residues [36] . There are, however, two significant issues in the use of such techniques for constructing thermostability curves of GPCRs. First, many GPCRs are too unstable to be purified to the level required for these measurements. Secondly, none of these methods takes into account the requirement for the protein to retain its native pharmacology. An alternative is to measure thermostability in conjunction with radioligand binding on detergent solubilized receptors to determine the temperature where a GPCR loses the ability to bind ligand [37] .
Radioligand binding is also a useful tool to track protein folding during purification. The B max value is a measure of the amount of ligand binding to a protein sample, and over Figure 3 The effect of stabilization on GPCR monodispersity FSEC profiles for GFP-tagged CRF-1 (corticotropin-releasing factor 1) WT receptor, in a stabilized antagonist form, and in a highly stabilized antagonist form.
the course of purification a significant increase should be observed. For example, assuming a GPCR with a molecular mass of 50 kDa and a 1:1 stoichiometry of protein to ligand, a pure protein should have a B max value of 20 nmol/mg. This is usually extremely challenging to achieve, but the maximum theoretical binding has been obtained for GPCRs such as the neurotensin receptor [38] . Unfortunately, suitable radioligands are not readily available for every GPCR, and in many cases, the requirement for a high-affinity ligand to be present throughout purification to maintain receptor stability compromises the use of binding assays. The use of labelfree technologies such as SPR (surface plasmon resonance) offers an alternative to radioligand-binding assays. SPR does not require a labelled ligand to assess binding, and, by immobilizing and washing the receptor, binding can often be estimated even if a ligand has been present throughout the purification process. SPR relies on changes in mass at the sensor surface, and can be used to estimate the proportion of protein that is able to bind the ligand, although it is important to take into account the relative proportions of protein and detergent present when calculating the mass of the GPCR [39] .
Crystallization
Of the GPCR crystal structures that have been solved to date, the vast majority have involved the use of detergents such as alkyl maltosides, glucosides and neopentyl glycols, although rhodopsin has been crystallized in a number of different detergents, including a mix of C 8 E 4 (n-octyltetraoxyethylene) and LDAO (N,N-dimethyldodecylamine N-oxide) [40] . The choice of the specific detergent from which the protein is crystallized is predominantly driven by the method of crystallization. VD (vapour diffusion) crystallization requires the DDM to be replaced by harsher shorter chain detergents and so far has only been used for StaRs. Hence the β 1 -adrenergic StaR was crystallized by VD in OTG (octylthioglucoside) [6] and HEGA-10 ® supplemented with CHS (cholesteryl hemisuccinate) [41] , whereas the adenosine A 2A StaR was crystallized in the presence of NG (nonyl glucoside) [7] or OTG [8, 42] . LCP (lipidic cubic phase) crystallization offers a method where samples do not need to be exchanged from DDM into a harsher detergent, as, unlike VD, the detergent primarily acts as a vehicle enabling the receptors to be transferred into the lipidic phase. In such cases, the receptor does not require stabilzation for solubilization and purification, but a fusion protein is required to assist rapid crystallization before the protein starts to denature. The combination of using a T4 fusion protein, solubilized and purified in DDM, and crystallized using LCP, has been successful for several GPCRs, including adenosine A 2A [28] , β 2 -adrenergic [43] , CXCR4 chemokine [22] , dopamine D3 [24] , histamine H 1 [16] , κ-opioid [44] , nociceptin/orphanin FQ [12] and the S1P 1 receptor [23] . In the case of the β 2 -adrenergic receptor G s complex structure it was noted that the complex was only stable once the detergent was exchanged from DDM to LMNG (lauryl maltose neopentyl glycol) [45] . The neopentyl glycol class of detergents [46] offers an increase in thermostability over DDM, and has aided the structural determination of a number of other receptors including the previously mentioned β 2 -adrenergic, muscarinic M 2 and M 3 [33, 21] , δ-opioid [31] and μ-opioid [29] receptor structures. In the absence of thermostabilizing mutations a high-affinity ligand is usually required to stabilize the receptor during purification and crystallization, whereas StaRs require less stabilization from the ligand, allowing co-structures with small, low-affinity ligands such as adenosine and caffeine to be obtained [7] .
Future developments
Although the rate of solution of novel X-ray structures of GPCRs has increased impressively in recent years, structures are available for only approximately 3% of human GPCRs, and all have been from family A to date. Many more will emerge in the next few years, and it is only a matter of time before structures from families B and C are reported. Work currently underway is informed by previous studies, and additional experiences will continue to make efforts with new receptors more likely to succeed. As more structures are reported, and those of further members of groups of related receptors emerge, demands for structures for GPCR drug discovery will become as prevalent as they are for soluble proteins. Structures with antibodies directed towards the extracellular regions of the GPCRs will also be informative for the discovery of therapeutic proteins. Details of the interactions with G-proteins are now emerging [47] , and there is more to be revealed, as well as complexes with alternative signalling partners such as the β-arrestins.
Although the techniques have been developed primarily to aid X-ray crystallography, purified GPCRs can also be used for other biophysical techniques such as NMR [48] and SPR [49] . Similar to the X-ray structures, these promise to enable better understanding of interactions with partners, and the discovery of new ligands, for example via screening of fragment libraries, and the combination of a number of biophysical methods has already proved successful for drug discovery [50] .
